Catastrophic antiphospholipid syndrome in the second trimester of pregnancy.
Elchalal
Uriel
U
Department of Obstetrics and Gynecology, Hadassah University Hospital and Hebrew University-Hadassah Medical School, Jerusalem, Israel. elchalal@huji.ac.il
Gabbay
Ezra
E
Nadjari
Michel
M
Varon
David
D
Zelig
Orly
O
Ben-Chetrit
Eldad
E
D000028:Abortion, Induced; D000328:Adult; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D000925:Anticoagulants / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D016736:Antiphospholipid Syndrome / Q000175:diagnosis* / Q000188:drug therapy; D017984:Enoxaparin / Q000627:therapeutic use; D017809:Fatal Outcome; D005260:Female; D017359:HELLP Syndrome / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D006854:Hydrocortisone / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011247:Pregnancy; D011262:Pregnancy Trimester, Second
D000893:Anti-Inflammatory Agents; D000925:Anticoagulants; D018931:Antineoplastic Agents, Hormonal; D017984:Enoxaparin; D011241:Prednisone; D006854:Hydrocortisone